April 23, 2014 - The court approved the settlement, entered the orders approving the plan of allocation, the motion for attorneys’ fees and expenses, and dismissed the action with prejudice.
January 28, 2014 - The court preliminarily approved the settlement.

December 20, 2013 - Parties filed a stipulation of settlement.

June 24, 2013 - The court granted the dismissal of all claims against two individual defendants with prejudice.

August 8, 2012 - KV Pharmaceutical Company filed a notice of filing for bankruptcy.

June 15, 2012 - The U.S. Court of Appeals for the Eighth Circuit issued a mandate on the June 4, 2012 opinion and order.

June 4, 2012 - The U.S. Court of Appeals for the Eighth Circuit affirmed in part and reversed in part the decision of the district court and remanded the case for further proceedings.

November 1, 2010 - The lead plaintiffs filed an amended notice of appeal from the October 20, 2010 order.

October 20, 2010 - The court denied the lead plaintiffs' motion for relief.

March 18, 2010 - The lead plaintiffs filed a notice of appeal and a motion for relief from the order of dismissal.

February 22, 2010 - The court granted the defendants' motions to dismiss.

July 27, 2009 - The defendants filed numerous motions to dismiss.

May 22, 2009 - The lead plaintiffs filed an amended consolidated complaint on behalf of investors who purchased shares of KV Pharmaceutical Company, class A and class B stock (NYSE: KV.A and NYSE: KV.B) and 7% cumulative convertible Preferred Stock (NYSE: KVPHP) between June 15, 2004 and January 23, 2009. The lead plaintiffs allege that the defendants violated the Securities Exchange Act of 1934 by issuing false and misleading statements between June 15, 2004 and January 23, 2009.

April 28, 2009 - The court issued an amended lead plaintiff and counsel order.

April 15, 2009 - The lead plaintiffs and lead counsel were appointed and all cases were consolidated.

February 2, 2009 - Lead plaintiff motions were filed.

January 21, 2009 - An additional investor filed a complaint.

January 9, 2009 - Another investor filed a complaint.

December 02, 2008 - An investor in shares of KV Pharmaceutical Company, class A and class B stock (NYSE: KV.A and NYSE: KV.B) and 7% cumulative convertible Preferred Stock (NYSE: KVPHP), filed a lawsuit in in the U.S. District Court for the Eastern District of Missouri against KV Pharmaceutical Company over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between February 15, 2008 and November 12, 2008.

According to the complaint the plaintiff alleges that KV Pharmaceutical Company and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing materially false and misleading statements about KV Pharmaceutical Company’s compliance with federal regulations concerning the manufacturing and marketing of certain generic drug products as well as its current and future financial prospects. Then, on November 13, 2008, KV Pharmaceutical Company announced that it would be unable to file its Form 10-Q for the quarter ended September 30, 2008 due to a continuing investigation by the KV Pharmaceutical Company’s Audit Committee into allegations of management misconduct concerning recalls of the KV Pharmaceutical Company’s drug products and as a result of this news the price of KV Pharmaceutical Company common stock fell from $14.26 per share to $5.90 per share – a drop of nearly 59% - on extremely heavy volume of more than 6.6 million shares, 33 times the stock’s average trading volume, so the lawsuit.

Two days before Christmas, KV Pharmaceutical Company lost half its value in New York trading after the drug maker, announcing a fourth recall of medicines that may contain excess doses, stopped shipping prescription tablets, according to Bloomberg News.

In late December, KV Pharmaceutical Company reportedly said it suspended shipments of all its drugs in tablet form and recalled a single production lot of the painkiller Hydromorphone HCl 2 mg tablets because the tablets are oversized.